Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vericel Corporation - Common Stock (NQ:VCEL)

34.88 +1.29 (+3.84%)
Streaming Delayed Price Updated: 12:27 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vericel Corporation - Common Stock

< Previous 1 2 3 4 Next >
This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
MediWound Revenue Jumps 43% in Q2
Via The Motley Fool
Vericel Corp (NASDAQ:VCEL): A High-Growth Stock with a Promising Technical Setup
Vericel Corp (VCEL) is a high-growth biotech stock with strong fundamentals and a promising technical setup, making it a potential breakout candidate for investors. 
Via Chartmill
Vericel Q2 Revenue Jumps 20%
Via The Motley Fool
Topics Intellectual Property
Vericel Corp (NASDAQ: VCEL) Posts Mixed Q2 2025 Results with Revenue Miss and EPS Beat
Vericel Corp (VCEL) posted mixed Q2 2025 results with revenue missing estimates but EPS beating expectations. Shares fell 6.5% pre-market despite strong MACI growth and margin expansion. 
Via Chartmill
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Where Vericel Stands With Analysts
 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
What 7 Analyst Ratings Have To Say About Vericel
 
Via Benzinga
VERICEL CORP (NASDAQ:VCEL) – A Strong Growth Stock with Technical Breakout Potential
VERICEL CORP (NASDAQ:VCEL) shows strong growth fundamentals and a technical breakout pattern, making it a stock to watch in the biotech sector. 
Via Chartmill
VERICEL CORP (NASDAQ:VCEL) – A Strong Growth Stock with Technical Breakout Potential
VERICEL CORP (NASDAQ:VCEL) shows strong revenue and earnings growth, backed by a solid balance sheet and a promising technical breakout pattern. 
Via Chartmill
What Analysts Are Saying About Vericel Stock
 
Via Benzinga
VERICEL CORP (NASDAQ:VCEL) – A Strong Growth Stock with a Technical Setup
VERICEL CORP (NASDAQ:VCEL) shows strong growth potential with solid profitability and a promising technical setup, making it a stock worth watching. 
Via Chartmill
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Beyond The Numbers: 5 Analysts Discuss Vericel Stock
 
Via Benzinga
Earnings Preview For Vericel
 
Via Benzinga
The Analyst Verdict: Vericel In The Eyes Of 7 Experts
 
Via Benzinga
Expert Ratings For Vericel
 
Via Benzinga
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
The Latest Analyst Ratings For Vericel
 
Via Benzinga
Apple To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
A Glimpse Into The Expert Outlook On Vericel Through 4 Analysts
 
Via Benzinga
Critical Insights From Vericel Analyst Ratings: What You Need To Know
 
Via Benzinga
Analyst Scoreboard: 5 Ratings For Vericel
 
Via Benzinga
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
The 3 Highest-Rated Medical Stocks You Can Buy Today
Are you looking for highly-rated medical stocks? These three contenders are offering substantial growth over the long term. 
Via InvestorPlace
VCEL Stock Earnings: Vericel Beats EPS, Beats Revenue for Q1 2024
VCEL stock results show that Vericel beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23. 
Via Talk Markets
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.